美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Alamar Biosciences, Inc.

36.57

+8.5830.65%

盤後：36.40-0.1700-0.46%19:55 EDT

成交量：155.83萬

成交額：5,533.66萬

市值：25.35億

市盈率：-58.33

高：38.54

開：29.00

低：28.03

收：27.99

52周最高：38.54

52周最低：18.85

股本：6,931.12萬

流通股本：1,293.75萬

量比：6.92

換手率：12.05%

股息：- -

股息率：- -

每股收益(TTM):-0.6270

每股收益(LYR):-2.5873

淨資產收益率：-33.57%

總資產收益率：-13.53%

市淨率：-14.23

市盈率(LYR):-14.13

資料載入中...

總覽公司新聞資訊公告

Alamar Biosciences攜手阿爾茨海默病數據倡議與Gates Ventures，深化全球合作

財報前瞻｜Alamar Biosciences, Inc.本季度營收預計約2,593.98萬美元，機構觀點偏看多

高盛系免疫療法新鋭Attovia(ATTO.US)衝刺納斯達克：最高募資2.125億美元，成生物科技IPO熱潮最新註腳

Alzpath 擴大與 Alamar Biosciences 的戰略合作，推動阿爾茨海默病臨床診斷進步

Alamar Biosciences推出首個基於血液的Emtbr-tau多重免疫檢測方法，該標誌物為阿爾茨海默病研究最重要生物標誌物之一

美銀全球研究開始覆蓋Alamar Biosciences，給予中性評級及27美元目標價

Leerink Partners首予Alamar Biosciences「跑贏大盤」評級，目標價35美元

美國研究綜述-Accuray、Aevex、Zoetis

生物技術公司奧德賽計劃在美國首次公開募股（IPO）中尋求8.1億美元的估值

異動解讀 | Alamar Biosciences IPO後受技術優勢及投資者信心推動，盤中大漲5%

精準蛋白質組學領域領導者Alamar Biosciences成功登陸納斯達克

異動解讀 | IPO首秀開盤價高於發行價，Alamar Biosciences盤中大漲32.94%

美股異動 | Alamar Biosciences(ALMR.US)登陸美股市場開盤升逾34%

BUZZ-Alamar Biosciences 納斯達克首秀有望高於發行價開盤

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ALMR/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ALMR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALMR\",,,,,undefined,":{"symbol":"ALMR","market":"US","secType":"STK","nameCN":"Alamar Biosciences, Inc.","latestPrice":36.57,"timestamp":1786478400000,"preClose":27.99,"halted":0,"volume":1558330,"hourTrading":{"tag":"盘后","latestPrice":36.4,"preClose":36.57,"latestTime":"19:55 EDT","volume":17216,"amount":629609.2651,"timestamp":1786492501007,"change":-0.17,"changeRate":-0.004649,"amplitude":0.0484},"delay":0,"changeRate":0.3065380493033227,"floatShares":12937500,"shares":69311200,"eps":-0.627,"marketStatus":"未開盤","change":8.58,"latestTime":"08-11 16:00:00 EDT","open":29,"high":38.54,"low":28.03,"amount":55336645.80759001,"amplitude":0.375491,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.627,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1786521600000},"marketStatusCode":0,"adr":0,"listingDate":1776398400000,"exchange":"NASDAQ","adjPreClose":27.99,"preHourTrading":{"tag":"盘前","latestPrice":29,"preClose":27.99,"latestTime":"09:27 EDT","volume":299,"amount":8473.014459,"timestamp":1786454830025,"change":1.01,"changeRate":0.036084,"amplitude":0.036084},"postHourTrading":{"tag":"盘后","latestPrice":36.4,"preClose":36.57,"latestTime":"19:55 EDT","volume":17216,"amount":629609.2651,"timestamp":1786492501007,"change":-0.17,"changeRate":-0.004649,"amplitude":0.0484},"volumeRatio":6.921783},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALMR\",,,,,undefined,":{"symbol":"ALMR","floatShares":12937500,"roa":"-13.53%","roe":"-33.57%","lyrEps":-2.587299,"volumeRatio":6.921783,"shares":69311200,"dividePrice":0,"high":38.54,"amplitude":0.375491,"preClose":27.99,"low":28.03,"week52Low":18.845,"pbRate":"-14.23","psRate":"29.08","week52High":38.54,"institutionHeld":0,"latestPrice":36.57,"eps":-0.627,"divideRate":0,"volume":1558330,"delay":0,"ttmEps":-0.627,"open":29,"prevYearClose":17,"prevWeekClose":28.46,"prevMonthClose":25.36,"prevQuarterClose":27.09,"fiveDayClose":27.11,"twentyDayClose":27.05,"sixtyDayClose":22.51},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALMR\",params:#limit:5,,,undefined,":[{"date":"2026-08-10","symbol":"ALMR","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2026/06","expectedEps":-0.36,"defaultRemindTime":1786392000000,"name":null,"time":"盤後","dateTimestamp":1786334400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALMR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ALMR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.4,"hold":0.2,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.4,"analysts":5,"updateTime":1779422400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ALMR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ALMR","date":"2026-08-10","current":-57.631579,"percent":0.197183,"low":-61.051551,"twenty":-45.349934,"median":-40.062933,"eighty":-33.17246,"high":-30.427746,"avg":-41.276042,"sd":8.3599,"marketCap":1972596353},"quantilePoints":[{"date":"2026-05-01","current":-57.277289,"twenty":-59.990183,"median":-57.277289,"eighty":-56.655108,"marketCap":1707951482},{"date":"2026-05-08","current":-54.120633,"twenty":-59.175857,"median":-56.408065,"eighty":-54.495772,"marketCap":1613823165},{"date":"2026-05-15","current":-35.878919,"twenty":-57.629553,"median":-54.669617,"eighty":-53.99338,"marketCap":1560194796},{"date":"2026-05-22","current":-35.066025,"twenty":-56.9113,"median":-54.440874,"eighty":-34.919385,"marketCap":1524846092},{"date":"2026-05-29","current":-31.495666,"twenty":-56.325717,"median":-53.802501,"eighty":-32.467951,"marketCap":1369589035},{"date":"2026-06-05","current":-34.253131,"twenty":-55.282649,"median":-35.878919,"eighty":-32.646469,"marketCap":1489497387},{"date":"2026-06-12","current":-35.368868,"twenty":-54.724515,"median":-34.699426,"eighty":-32.401007,"marketCap":1538015217},{"date":"2026-06-18","current":-32.196986,"twenty":-54.651317,"median":-34.308917,"eighty":-32.158732,"marketCap":1400085957},{"date":"2026-06-26","current":-42.828368,"twenty":-54.587269,"median":-35.066025,"eighty":-32.350002,"marketCap":1862391567},{"date":"2026-07-02","current":-41.648874,"twenty":-54.495772,"median":-35.368868,"eighty":-32.60184,"marketCap":1811101290},{"date":"2026-07-10","current":-42.206743,"twenty":-54.303628,"median":-36.436788,"eighty":-32.691099,"marketCap":1835360205},{"date":"2026-07-17","current":-39.76806,"twenty":-53.99338,"median":-39.098618,"eighty":-32.700662,"marketCap":1729314090},{"date":"2026-07-24","current":-41.266336,"twenty":-53.295956,"median":-39.903543,"eighty":-32.786733,"marketCap":1794466605},{"date":"2026-07-31","current":-39.959329,"twenty":-52.542305,"median":-39.576791,"eighty":-32.978002,"marketCap":1737631433},{"date":"2026-08-07","current":-44.788877,"twenty":-45.298929,"median":-40.039025,"eighty":-33.153333,"marketCap":1947644326},{"date":"2026-08-10","current":-45.362685,"twenty":-45.349934,"median":-40.062933,"eighty":-33.17246,"marketCap":1972596353}],"updateTime":1786478292481},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALMR\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1165363440","title":"Alamar Biosciences攜手阿爾茨海默病數據倡議與Gates Ventures，深化全球合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1165363440","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165363440?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 04:05","pubTimestamp":1786392312,"startTime":"0","endTime":"0","summary":"Alamar Biosciences（简称：ALMR）正积极拓展其全球战略版图，与阿尔茨海默病数据倡议（Alzheimer’s Disease Data Initiative）以及Gates Ventures达成更广泛的合作伙伴关系。这一举措，旨在通过数据共享与技术协同，加速对阿尔茨海默病的研究与疗法开发。合作方将整合各自资源，推动全球范围内的疾病数据整合与创新诊断工具的应用。Alamar Biosciences的管理层表示，此合作将进一步提升其平台在神经退行性疾病领域的应用潜力，为患者群体带来更精准的诊断方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ALMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130899284","title":"財報前瞻｜Alamar Biosciences, Inc.本季度營收預計約2,593.98萬美元，機構觀點偏看多","url":"https://stock-news.laohu8.com/highlight/detail?id=1130899284","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130899284?lang=zh_tw&edition=fundamental","pubTime":"2026-08-03 08:55","pubTimestamp":1785718537,"startTime":"0","endTime":"0","summary":"Alamar Biosciences, Inc.将于2026年08月10日盘后发布2026年第二季度财报，市场聚焦收入延续性与亏损收窄节奏。市场一致预期显示，本季度Alamar Biosciences, Inc.营收预计为2,593.98万美元，同比增速记录为0.00%；调整后每股收益预计为—0.33美元，同比增速记录为0.00%，公司层面暂未披露本季度的毛利率与净利率指引，亦未提供本季度收入指引。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Alamar Biosciences, Inc.本季度营收预计约2,593.98万美元，机构观点偏看多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655844683","title":"高盛系免疫療法新鋭Attovia(ATTO.US)衝刺納斯達克：最高募資2.125億美元，成生物科技IPO熱潮最新註腳","url":"https://stock-news.laohu8.com/highlight/detail?id=2655844683","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655844683?lang=zh_tw&edition=fundamental","pubTime":"2026-07-30 11:39","pubTimestamp":1785382784,"startTime":"0","endTime":"0","summary":"发行概览：从1亿美元到2.125亿美元，需求推动规模扩大Attovia于7月14日首次提交IPO申请时，计划募资约1亿美元。以区间中点计算，Attovia的完全稀释市值约为6.49亿美元。截至2026年3月31日，公司累计融资达2.558亿美元。Alamar至今仍是Attovia的重要股东。市场背景：生物科技IPO的“黄金窗口”Attovia选择此时上市绝非偶然——2026年正成为生物科技IPO的“大年”。至少还有六家生物科技公司已在7月提交IPO申请，预计将在夏末前完成定价。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1473953.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4226","LU0096364046.USD","LU0106831901.USD","LU0061475181.USD","LU1868837300.USD","LU2471134523.USD","LU2237438978.USD","LU1868836914.USD","LU1804176565.USD","LU2237443549.SGD","LU1791807156.HKD","LU0345770308.USD","LU2237443895.HKD","LU1868837136.USD","LU2237443978.SGD","LU1894683264.USD","LU2237443465.HKD","IE00B19Z3B42.SGD","LU2237443622.USD","LU2471134796.USD","LU0942090050.USD","BK4550","BK4552","BK4588","IE0002270589.USD","IE00B19Z3581.USD","BK4533","LU2750360641.GBP","IE0034235188.USD","LU1894683348.USD","IE00BSNM7G36.USD","GS","LU0251142724.SGD","BK4121","LU0742534661.SGD","LU2471134879.HKD","LU2471134952.CNY","LU2265009873.SGD","LU0345770993.USD","LU1868836591.USD","IE0004091025.USD","LU0048573561.USD","BK4504","ATTO","BK4585","IE00BFXG1179.USD","LU0251131958.USD","GSX","BK4143","LU1868836757.USD","LU2237443382.USD","BK4127","IE0004086264.USD","LU0868494617.USD","ALMR","BK4516","LU1668664300.SGD","LU2750360997.AUD","LU0868494708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120675244","title":"Alzpath 擴大與 Alamar Biosciences 的戰略合作，推動阿爾茨海默病臨床診斷進步","url":"https://stock-news.laohu8.com/highlight/detail?id=1120675244","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120675244?lang=zh_tw&edition=fundamental","pubTime":"2026-07-23 20:35","pubTimestamp":1784810143,"startTime":"0","endTime":"0","summary":"Alzpath 宣布，已进一步扩展与 Alamar Biosciences 的战略合作协议。双方旨在携手推进阿尔茨海默病的临床诊断技术。通过此次深化合作，Alzpath 将充分利用 Alamar Biosciences 的创新平台，加速相关诊断工具的开发与应用。这一举措有望为阿尔茨海默病的早期检测与精准诊断带来显著突破，从而更好地满足患者和医疗系统的迫切需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ALMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111524499","title":"Alamar Biosciences推出首個基於血液的Emtbr-tau多重免疫檢測方法，該標誌物為阿爾茨海默病研究最重要生物標誌物之一","url":"https://stock-news.laohu8.com/highlight/detail?id=1111524499","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111524499?lang=zh_tw&edition=fundamental","pubTime":"2026-07-07 21:16","pubTimestamp":1783430177,"startTime":"0","endTime":"0","summary":"Alamar Biosciences推出了首个基于血液的Emtbr-tau多重免疫检测方法。Emtbr-tau是阿尔茨海默病研究领域最为关键的生物标志物之一。这一创新检测方案的问世，标志着在利用血液样本进行神经退行性疾病精准诊断方面取得了重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMR","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180385750","title":"美銀全球研究開始覆蓋Alamar Biosciences，給予中性評級及27美元目標價","url":"https://stock-news.laohu8.com/highlight/detail?id=1180385750","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180385750?lang=zh_tw&edition=fundamental","pubTime":"2026-05-12 19:51","pubTimestamp":1778586675,"startTime":"0","endTime":"0","summary":"美银全球研究（BofA Global Research）已开始对生物科技公司Alamar Biosciences进行跟踪研究，并在其首份报告中给予该公司“中性”评级。与此同时，分析师为该股设定了27美元的目标价位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMR","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147513482","title":"Leerink Partners首予Alamar Biosciences「跑贏大盤」評級，目標價35美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1147513482","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147513482?lang=zh_tw&edition=fundamental","pubTime":"2026-05-12 18:07","pubTimestamp":1778580462,"startTime":"0","endTime":"0","summary":"投资银行Leerink Partners宣布，首次覆盖生物科技公司Alamar Biosciences，并给予其“跑赢大盘”的评级。该机构为该公司设定了35美元的目标股价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ALMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634298470","title":"美國研究綜述-Accuray、Aevex、Zoetis","url":"https://stock-news.laohu8.com/highlight/detail?id=2634298470","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634298470?lang=zh_tw&edition=fundamental","pubTime":"2026-05-12 15:22","pubTimestamp":1778570557,"startTime":"0","endTime":"0","summary":"美国研究综述-Accuray、Aevex、Zoetis路透5月12日 - 周二，华尔街的证券分析师们下调了多家在美国上市公司的评级和目标股价，其中包括Accuray、Aevex和Zoetis。股票按字母顺序排列。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL4T41P0LY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGNX","CYTK","VCTR","ELVN","HIMY","MOS","LU1496350171.SGD","SGI","SPG","WPC","ZTS","VSNT","GTM","PSIX","SIBN","PLNT","TOST","CVS","BX","SKYE","TRGP","SNDA","BK4585","BILL","000338","ARES","APO","ARAY","IE00BFXG1179.USD","BAM","AVEX","HIYY","CE","AGM","FTV","TGT","LU1244550221.USD","ALMR","ASTH","AMAT","CEVA","LQDA","HIMS","HIMZ","TXG","HMYY","BN","LENZ","LU2023250504.SGD","KKR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632493274","title":"生物技術公司奧德賽計劃在美國首次公開募股（IPO）中尋求8.1億美元的估值","url":"https://stock-news.laohu8.com/highlight/detail?id=2632493274","media":"路透中文","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632493274?lang=zh_tw&edition=fundamental","pubTime":"2026-05-04 18:48","pubTimestamp":1777891733,"startTime":"0","endTime":"0","summary":"更新版 2-生物技术公司奥德赛计划在美国首次公开募股中寻求8.1亿美元的估值全文补充了细节。路透5月4日 - 生物制药公司奥德赛治疗周一表示，随着投资者对药物开发商的热情高涨，该公司计划在美国首次公开募股中寻求高达8.099亿美元的估值。近几周，美国IPO市场强势反弹，为未来数月上市热潮奠定了基础。该公司计划在纳斯达克上市，股票代码为“ODTX”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nL4T41H0OX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345770308.USD","ANV","NVDA","NVDG","NVDX","XE","HK0000304805.HKD","LU2097344357.USD","NVDD","3NVD.UK","NVD3.UK","NVD","NVDU","SNVD.UK","2NVD.UK","DIPS","BK4598","LU0069063385.USD","LU0345769128.USD","IE0009356076.USD","LU0211328371.USD","LU0466842654.USD","LU2326559502.SGD","KLRA","LU2168563687.JPY","NVII","LU2023250330.USD","SG9999015952.SGD","NVDB","NVDY","NVDS.UK","NVIW.SI","NVD2.UK","LU1116320901.HKD","NVDS","LU1280957306.USD","LU1645745479.HKD","LU2111349929.HKD","NVDW","LU0174119429.USD","NVDQ","NVDO","SG9999000418.SGD","LU0354030511.USD","SG9999018865.SGD","IE00BDRTCR15.USD","NVDL","BK4527","LU2430703251.USD","ALMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186885979","title":"異動解讀 | Alamar Biosciences IPO後受技術優勢及投資者信心推動，盤中大漲5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1186885979","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186885979?lang=zh_tw&edition=fundamental","pubTime":"2026-04-20 22:16","pubTimestamp":1776694619,"startTime":"0","endTime":"0","summary":"Alamar Biosciences, Inc.（股票代码：ALMR）今日盘中股价大幅上涨5.00%，市场表现强劲。消息面上，该公司于近期成功登陆纳斯达克，完成首次公开募股（IPO）。作为精准蛋白质组学领域的领导者，Alamar Biosciences自主研发的NULISA™技术平台在蛋白质检测方面具有超高灵敏度与特异性，其ARGO™ HT全自动高通量设备也已实现广泛的市场渗透，累计装机量超过100台，客户遍布全球25个国家。此外，知名风险投资机构启明创投作为公司重要的早期投资方，持续多轮支持其发展，并在IPO前持有约19.2%的股份，这进一步增强了市场对该公司长期成长潜力的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ALMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628716309","title":"精準蛋白質組學領域領導者Alamar Biosciences成功登陸納斯達克","url":"https://stock-news.laohu8.com/highlight/detail?id=2628716309","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628716309?lang=zh_tw&edition=fundamental","pubTime":"2026-04-20 10:28","pubTimestamp":1776652080,"startTime":"0","endTime":"0","summary":"上海2026年4月20日 /美通社/ -- 北京时间2026年4月17日，启明创投投资企业、精准蛋白质组学领域领导者Alamar Biosciences成功登陆纳斯达克，至此启明创投迎来开年第五个IPO。2020年，启明创投领投了Alamar Biosciences的A轮融资，并在B轮和C轮继续支持公司发展。IPO前启明创投持有Alamar Biosciences约19.2%的股份，是公司最重要的机构投资方之一。Alamar Biosciences成立于2018年，该公司致力于开发并商业化蛋白质组学技术，树立蛋白质检测与分析领域的金标准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/4937755_ZH37755_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4937755_ZH37755_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["QQQ","FTEC","BK1147","QQQA","TQQY","PSQ","IYW","NQmain","SQQQ","QLD","QQQM","QQQY","QID","NVIW.SI","JEPQ","QQQE","QDTE","GPIQ","BK4007","QYLG","TQQQ","ONEQ","QQQJ","ALMR","MNQmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107620656","title":"異動解讀 | IPO首秀開盤價高於發行價，Alamar Biosciences盤中大漲32.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=1107620656","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107620656?lang=zh_tw&edition=fundamental","pubTime":"2026-04-18 00:37","pubTimestamp":1776443855,"startTime":"0","endTime":"0","summary":"Alamar Biosciences, Inc.（股票代码：ALMR）今日盘中股价大幅上涨32.94%，引起了市场的广泛关注。消息面上，该公司今日在纳斯达克首次公开募股（IPO）上市。其股票发行价为每股17美元，而市场预计的开盘价达到22.50美元，显著高于发行价。此次IPO以发行区间上限价格出售了约1130万股股票，成功募集资金约1.913亿美元。Alamar Biosciences是一家专注于蛋白质组学的公司，开发了用于检测血液中低水平蛋白质生物标记物的仪器平台，该技术为疾病研究和诊断提供了有力工具。市场对其技术和增长前景的乐观情绪，推动了上市首日的强劲表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ALMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628783908","title":"美股異動 | Alamar Biosciences(ALMR.US)登陸美股市場 開盤升逾34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628783908","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628783908?lang=zh_tw&edition=fundamental","pubTime":"2026-04-18 00:07","pubTimestamp":1776442021,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周五，Alamar Biosciences(ALMR.US)登陆美股市场，开盘涨超34%，报22.91美元。IPO价格为17美元。Alamar Biosciences是一家总部位于美国加州的生物科技公司，专注于精准蛋白质组学技术的开发与应用。公司核心产品基于自研的NULISA平台，能够以极高灵敏度检测血液中的微量蛋白质标志物，从而帮助科研人员更早发现疾病、推动药物研发和精准医疗发展。其技术主要应用于阿尔茨海默症、帕金森等神经退行性疾病研究领域。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430272.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ALMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628078819","title":"BUZZ-Alamar Biosciences 納斯達克首秀有望高於發行價開盤","url":"https://stock-news.laohu8.com/highlight/detail?id=2628078819","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628078819?lang=zh_tw&edition=fundamental","pubTime":"2026-04-17 23:58","pubTimestamp":1776441483,"startTime":"0","endTime":"0","summary":"** 蛋白质生物标记物检测平台Alamar Biosciences ALMR.O纳斯达克首秀有望高于发行价开盘** 最近表示股票开盘价为每股22.50美元，而发行价为17美元** 总部位于加利福尼亚州弗里蒙特的ALMR在规模扩大的首次公开募股中，以15-17美元发行区间的上限价格，出售了约1,130万股股票，  募集资金1.913亿美元。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nL4S4101EC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMR","LU1718418525.SGD","MDIT","LU0417517546.SGD","IE0034235188.USD","LU0314106906.USD","LU0648001328.SGD","LU1363072403.SGD","LU1791807156.HKD","LU0070302665.USD","IE0002270589.USD","IE00BZ1G4Q59.USD","LU2265009873.SGD","LU1880398554.USD","LU1506573853.SGD","LU1267930227.SGD","LU2129689514.USD","IE0001KFT4U8.USD","LU0234570918.USD","BAC","LU2129689431.USD","LU0170899867.USD","LU1668664300.SGD","LU0130518102.USD","LU0320765646.SGD","LU0321505439.SGD","LU1496350171.SGD","LU0477156953.USD","LU0211331839.USD","LU0310800965.SGD","MNSH","IE00B7SZLL34.SGD","SF","IE00B19Z3581.USD","IE00BBT3K403.USD","LU1035773651.USD","LU1366192091.USD","BK4534","LU0256863902.USD","LU1074936037.SGD","LU0203347892.USD","LU1804176565.USD","BK4581","LU0052756011.USD","BK4588","LU0053666078.USD","LU1201861249.SGD","BK4504","LU0128525689.USD","LU1201861165.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":14,"code":"91000000","status":"200"}]}}